

# Vladimir O. Talibov

---

Last update: April 11, 2021

Svartbäcksgatan 19  
SE 75332  
Uppsala, Sweden

<https://vtalibov.xyz>  
[mail@vtalibov.xyz](mailto:mail@vtalibov.xyz)

- Summary** A protein biochemist with an interest in ligand discovery. Experienced in biophysical and kinetic methods.
- Skills** Experimental: Biophysical methods (SPR biosensors, TSA, MST), protein techniques, expression&purification, macromolecular crystallography  
Computer: Linux, RDKit, KNIME  
Languages: English, Russian, Swedish (basic)  
Expertise: Biophysical methods, enzymology, small molecules.
- Experience**
- Senior Scientist* Mar 2021 – current  
Sprint Bioscience AB, Huddinge, Sweden
- Support of FBLD projects as a member of Protein Science Team
  - Structural biology (MX)
  - Protein biochemistry.
- Researcher* Aug 2019 – Feb 2021  
MAX IV Laboratory, Lund, Sweden
- Development of operation protocols for MAX IV fragment screening facility
  - Design, curation and maintenance of in-house fragment library
  - BioMAX user support as a beamline scientist, including on-call service.
- PhD student, Researcher* Apr 2014 – Jun 2019  
Uppsala University, Uppsala, Sweden
- Development of biophysical and enzymatic assays for ligand discovery
  - Maintenance of biosensors and chromatographic equipment.
  - Teaching (20%, MSc-level courses)
- Laboratory Assistant* Jul 2012 – Feb 2014  
OOO "Biochip-IMB", Moscow, Russia
- Development and validation of multiplex clinical diagnostics assays
  - QC of proteins, synthetic oligonucleotides and reactive small molecules.
- Education**
- PhD in Biochemistry* 2014 – 2019  
Uppsala University, Uppsala, Sweden  
Advisor: Prof. U. Helena Danielson  
["Interaction kinetic analysis in drug design, enzymology and protein research"](#).
- BSc&MSc in Chemistry* 2008 – 2013  
Moscow State University, Moscow, Russia  
Specialisation in bioorganic chemistry.
- Interests** Molecular recognition, early stage lead discovery, screening techniques.

## Publications

Research articles: 9; details are available at [GScholar](#).

Other: reviews - 2, book chapters - 1, patents - 1.

- [1] V. O. Talibov\*, E. Fabini\*, E. FitzGerald, D. Tedesco, D. Eriksson, M. J. Talu, M. M. Rachman, F. Mihalic, E. Manoni, M. Naldi, et al. “Discovery of an allosteric ligand binding site in SMYD3 lysine methyltransferase”. In: *ChemBioChem* 22 (2021).
- [2] G. M. Lima, V. O. Talibov, E. Jagudin, C. Sele, M. Nyblom, W. Knecht, D. T. Logan, T. Sjögren, and U. Mueller. “FragMAX: the fragment-screening platform at the MAX IV Laboratory”. In: *Acta Crystallogr., Sect. D: Struct. Biol.* 76.8 (2020), pp. 771–777.
- [3] A. Rogstam, M. Nyblom, S. Christensen, C. Sele, V. O. Talibov, T. Lindvall, A. A. Rasmussen, I. Andre, Z. Fisher, W. Knecht, and F. Kozielski. “Crystal Structure of Non-Structural Protein 10 from Severe Acute Respiratory Syndrome Coronavirus-2”. In: *Int. J. Mol. Sci.* 19.21 (2020), p. 7375.
- [4] T. Ursby, K. Åhnberg, R. Appio, O. Aurelius, A. Barczyk, A. Bartalesi, M. Bjelčić, F. Bolmsten, Y. Cerenius, R. B. Doak, et al. “BioMAX—the first macromolecular crystallography beamline at MAX IV Laboratory”. In: *J. Synchrotron Radiat.* 27.5 (2020).
- [5] J. Yang\*, V. O. Talibov\*, S. Peintner, C. Rhee, V. Poongavanam, M. Geitmann, M. R. Sebastiano, B. Simon, J. Hennig, D. Dobritzsch, U. H. Danielson, and J. Kihlberg. “Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1”. In: *ACS Omega* 8.5 (2020), pp. 3979–3995.
- [6] E. Fabini\*, V. O. Talibov\*, F. Mihalic, M. Naldi, M. Bartolini, C. Bertucci, A. Del Rio, and U. H. Danielson. “Unveiling the biochemistry of the epigenetic regulator SMYD3”. In: *Biochemistry* 58.35 (2019), pp. 3634–3645.
- [7] V. O. Talibov, V. Linkuvienė, U. H. Danielson, and D. Matulis. “Kinetic Analysis of Carbonic Anhydrase–Sulfonamide Inhibitor Interactions”. In: *Carbonic Anhydrase as Drug Target*. Springer, Cham, 2019, pp. 125–140.
- [8] V. Linkuviene\*, V. O. Talibov\*, U. H. Danielson, and D. Matulis. “Introduction of intrinsic kinetics of protein–ligand interactions and their implications for drug design”. In: *J. Med. Chem.* 61.6 (2018), pp. 2292–2302.
- [9] C. Seeger, V. O. Talibov, and U. H. Danielson. “Biophysical analysis of the dynamics of calmodulin interactions with neurogranin and Ca<sup>2+</sup>/calmodulin-dependent kinase II”. In: *J. Mol. Recognit.* 30.8 (2017), e2621.
- [10] V. O. Talibov, V. Linkuvienė, D. Matulis, and U. H. Danielson. “Kinetically selective inhibitors of human carbonic anhydrase isozymes I, II, VII, IX, XII, and XIII”. In: *J. Med. Chem.* 59.5 (2016), pp. 2083–2093.
- [11] V. I. Butvilovskaya, M. V. Tsybulskaya, A. A. Tikhonov, V. O. Talibov, P. V. Belousov, A. Y. Sazykin, A. M. Schwartz, S. A. Surzhikov, A. A. Stomakhin, O. N. Solopova, et al. “Preparation of recombinant serpins B3 and B4 and investigation of their specific interactions with antibodies using hydrogel-based microarrays”. In: *Mol. Biol.* 49.5 (2015), pp. 705–713.
- [12] B. Koos, G. Cane, K. Grannas, L. Löf, L. Arngården, J. Heldin, C.-M. Claesson, A. Klaesson, M. K. Hirvonen, F. M. De Oliveira, et al. “Proximity-dependent initiation of hybridization chain reaction”. In: *Nat. Commun.* 6 (2015), p. 7294.
- [13] G. U. Feyzkhanova, M. A. Filippova, V. O. Talibov, E. I. Dementieva, V. V. Maslennikov, Y. P. Reznikov, N. Offermann, A. S. Zasedatelev, A. Y. Rubina, and M. Fooke-Achterrath. “Development of hydrogel biochip for in vitro allergy diagnostics”. In: *J. Immunol. Methods* 406 (2014), pp. 51–57.